. 2006 Oct;50(10):3289–3296. doi: 10.1128/AAC.00699-06

TABLE 1.

CI values for inhibition of HIV-1_JR-FL envelope-mediated membrane fusion^a

First inhibitor	Target	IC₅₀ (nM)	IC₉₀ (nM)	Second inhibitor	CI₅₀	P value	CI₉₀	P value
PRO 140	CCR5	2.5	8.6	PRO 140	0.97 ± 0.07	0.13	0.96 ± 0.14	0.37
Maraviroc	CCR5	5.3	27	PRO 140	*0.61 ± 0.05*	<*0.0001*	*0.40 ± 0.06*	<*0.0001*
Vicriviroc	CCR5	3.2	16	PRO 140	*0.51 ± 0.05*	<*0.0001*	*0.36 ± 0.06*	<*0.0001*
TAK-779	CCR5	11	>200	PRO 140	*0.38 ± 0.08*	<*0.0001*	NA	NA
RANTES	CCR5	2.4	38	PRO 140	*0.59 ± 0.08*	*0.0022*	*0.43 ± 0.05*	*0.0002*
RANTES	CCR5	2.4	38	Maraviroc	*0.48 ± 0.03*	*0.0017*	*0.18 ± 0.01*	<*0.0001*
Vicriviroc	CCR5	3.2	16	Maraviroc	0.86 ± 0.03	0.016	0.75 ± 0.02	0.0033
Vicriviroc	CCR5	3.2	16	TAK-779	1.3 ± 0.18	0.12	NA	NA
2D7	CCR5	3.7	58	PRO 140	1.0 ± 0.14	0.61	1.9 ± 0.61	0.024
Enfuvirtide	gp41	8.6	66	PRO 140	0.84 ± 0.16	0.040	0.89 ± 0.20	0.19
PRO 542	gp120	8.9	91	PRO 140	0.96 ± 0.17	0.56	0.94 ± 0.19	0.45
BMS-378806	gp120	5.2	20	PRO 140	*1.3 ± 0.19*	*0.0015*	1.1 ± 0.22	0.19

Statistically significant results (P < 0.0023 after application of the Bonferroni correction for multiple comparisons) are indicated in italicized bold text. IC₅₀ and IC₉₀ denote values for the first inhibitor. NA, not applicable. TAK-779 did not consistently achieve 90% inhibition in the assay. CI values represent the means and standard deviations of 4 to 12 independent assays.